Skip to main content
Caplight Logo









Abintus Bio

Abintus Bio

Private
San Diego, CaliforniaHealthcare & Life Scienceshttps://abintusbio.com/

Last Round

Series B

Aug 15, 2022

Total Funding Raised

$15.65M

Company Overview

Abintus Bio is a biotechnology company that develops in vivo genetic medicines designed to reprogram a patient's immune cells directly within the body.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

in vivo gene therapyCAR-T therapyimmune cell reprogrammingviral vectoroff-the-shelf CAR-Tgenetic medicineoncologyhematologic malignanciessolid tumorsbiotechdrug discoverynext-gen CAR-T

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Abintus Bio Comparables

Compare Abintus Bio with similar companies based on industry and business-model similarity.

Abintus Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alaya.bio
87%
Eli Lilly and Company
83%
Umoja Biopharma
78%

Abintus Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 15, 2022
SeedApr 22, 2021

Key People

Founding team and executive leadership

Derek Ostertag

Founder, Chief Scientific Officer

Founding Team

Abintus Bio Investors

Notable investors and investment history

Abintus Bio Filings

Explore SEC and related filing metadata, where available.

Abintus Bio filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Abintus Bio's valuation, stock price, and market status.

Is Abintus Bio a public or private company?

Abintus Bio is a private company.

What is the current stock price of Abintus Bio?

Abintus Bio is a private company with no public stock price. No recent secondary market data is available.

How much is Abintus Bio worth (valuation)?

Valuation information for Abintus Bio is not publicly available.

Can I buy Abintus Bio stock?

Abintus Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Abintus Bio's last funding round?

Abintus Bio's most recent funding round was Series B on August 15, 2022.

Who are the main investors in Abintus Bio?

Key investors in Abintus Bio include Skyviews Life Science, Tech Coast Angels, Leukemia & Lymphoma Society, SeedFolio, BioBrit.

Will Abintus Bio IPO soon?

No public IPO plans have been announced for Abintus Bio.

How can I track Abintus Bio secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Abintus Bio's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSan Diego, California
Employee Range3
Year Founded2020
Last FundingAug 15, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?